What Management Said
Read the full Q3 2025 transcript ↗These statements may include our future expectations regarding financial results and guidance, market opportunities, and our growth. A reconciliation of these measures can be found in our earnings release as filed this morning and in our most recent 10-Q, which will also be available on our website. Then Dennis will review our financial results in more detail and provide our outlook. During the quarter, we made strong progress on our key initiatives that focused on new growth opportunities, margin improvement, and debt reduction.
While third-quarter revenue was lower than anticipated, this is reflective of timing instead of trajectory of our business. GLP-1 medications have fundamentally reshaped how consumers approach weight loss and wellness, and we are seeing this change is beginning to create demand for aesthetic procedures that align to our existing brand and capabilities. In the long term, we believe these procedures can account for a significant portion of AirSculpt's revenue and drive meaningful growth. In Q3, we adapted our marketing spend to align with the moderation in our revenue trend and prioritized initiatives that drive higher conversion.
Our third area of focus is maintaining strong financial discipline both in our margins and capital allocation. Year to date, we have generated more than $3 million in annualized cost savings net of investments in new growth initiatives. We expect to continue unlocking incremental value from our current operations, which we anticipate will expand our operating margin going forward. Turning to capital allocation, we have repaid nearly $18 million of our debt year to date.
What went well
- SG&A expense fell $6 million year over year, reflecting cost management activities and reduced equity-based compensation, and management noted cost controls helped bridge the revenue gap.
- Generated more than $3 million in annualized cost savings year to date, net of investments in new growth initiatives, with more opportunities being uncovered.
- Repaid nearly $18 million of debt year to date; gross debt was $57.9 million, the $5 million revolver remained undrawn, and leverage was 3.04x with full covenant compliance.
- Average revenue per case held at $12,587, above the midpoint of the historical $12,000-$13,000 range despite a roughly 3% year-over-year decline.
- Early skin-tightening and skin-excision pilots showed encouraging demand and higher conversion among GLP-1 patients, and Q4 same-store sales trends improved versus the year-to-date trend with stronger sequential and year-over-year Q4 margins implied.
What went wrong
- Revenue fell 17.8% year over year to $35 million, with same-store revenue down approximately 22%.
- Cases declined 15.2% to 2,780, with same-store cases down approximately 20%.
- Adjusted EBITDA dropped to $3 million from $4.7 million, and adjusted EBITDA margin fell to 8.7% from 11%, driven by the revenue decline.
- Net loss was $9.5 million, including two non-cash charges: a $4.6 million impairment on unused components of the internal technology/CRM project and roughly $2.3 million tied to closing the London center (plus ~$1 million of accelerated right-of-use asset amortization in SG&A).
- Cash flow from operations was a use of $225,000 versus a $1.8 million inflow in the prior-year quarter, and customer acquisition cost rose to roughly $3,100 per case from $2,900.
Guidance Changes
| Metric | Period | Current guidance |
|---|---|---|
| FY2025 revenue | FY2025 | approximately $153 million |
| FY2025 adjusted EBITDA | FY2025 | approximately $16 million (low end of range) |
| Q4 same-store sales | Q4 2025 | improving versus year-to-date trend; implied smaller year-over-year revenue decline |
| Q4 margins | Q4 2025 | implied EBITDA guidance highlights stronger margins sequentially and year over year |
Performance Breakdown
| Metric | YoY | Note |
|---|---|---|
| Revenue | -17.8% to $35 million | Challenging consumer environment for considered purchases; consumers hesitant to convert from leads/consults to purchase; muted skin-tightening uptake. |
| Same-store revenue | down approximately 22% | Softness in a challenging discretionary consumer environment; conversion pressure despite strong leads and consultations. |
| Cases | -15.2% to 2,780 | Same-store cases down approximately 20% amid weaker conversion of interested consumers to procedures. |
| Average revenue per case | down approximately 3% to $12,587 | Remained above the midpoint of the historical $12,000-$13,000 range. |
| Adjusted EBITDA | $3.0 million vs $4.7 million | Result of revenue declines, partly offset by cost controls. |
| Adjusted EBITDA margin | 8.7% vs 11% | Revenue declines outpaced cost reductions. |
| Cost of services (% of revenue) | 42.5% vs 41.8% | Dollar costs fell $2.9 million, but deleverage on lower revenue raised the ratio. |
| SG&A | down $6 million | Cost management activities and reductions in equity-based compensation. |
Earnings Call Themes & Trends
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| GLP-1 body-contouring opportunity | Skin tightening expected to address a broader sliver of demand | Opportunity seen as broader and more durable than initially expected; adding skin excision/removal procedures and fat removal to expand the total addressable market, with GLP-1 users converting better than non-GLP-1 users. | — |
| Skin-tightening pilot | Pilot began in Q2 | Expanded to multiple centers; found many clients have loose skin beyond what tightening can address, prompting new procedures. | — |
| Marketing and sales strategy | Standard lead-generation focus | Adapted spend to the moderating revenue trend, prioritizing higher-conversion initiatives; shifting to a more diversified media mix (influencer campaigns, television) plus new sales training and improved patient financing options. | — |
| Capital allocation / deleveraging | Debt repayment prioritized (Q2 repaid $16 million including $5 million revolver and $10 million prepayment) | Debt repayment remains the primary near-term focus; nearly $18 million repaid year to date; leverage 3.04x. | — |
| Center portfolio / London closure | London operating as part of the network | Decided to close the London center, its only unprofitable location, to focus resources on North America growth. | — |
| Leadership transition | CFO retirement previously announced | Michael Arthur to join as CFO in January 2026 as Dennis Dean retires after a transition; Dr. Aaron Rollins resigned from the board for personal reasons (no disagreement). | — |
Q&A Summary
Can you go deeper on where the cost cuts came from by line, and how sustainable the savings are into Q4 and next year?
The cost controls have been focused primarily on SG&A, including reductions in regional support positions, with some savings in cost of services. Management continues to press vendors and uncover additional opportunities, expects to sustain this diligent approach, and noted the cost controls are helping bridge the revenue softness heading into Q4.
What are you seeing with the standalone skin-tightening service and how fast will it roll out across the rest of the centers?
The thesis is proving out with clear demand for loose-skin solutions, but the pool of candidates for standalone skin tightening was smaller than expected because loose skin often exceeds what tightening can fix - which muted Q3 revenue. Skin tightening has been expanded to multiple centers, and results take three to six months to fully show, so it will take a few months to gather before-and-after cases before marketing and further expansion scale.
What new services are you looking to add to address the GLP-1 population?
The company sees a broader, more enduring opportunity for a suite of procedures beyond tightening, such as skin excisions/removals, many of which can be done in-clinic under local anesthesia and fit the existing model. Skin excision is in pilot now and is already seeing good demand even without marketing, and the company plans to keep expanding it.
You called Q3 a timing issue - what actually happened, especially since leads and consultations were stepping up last quarter?
The company continued to operate in a challenging consumer environment for considered purchases, unchanged from Q2. Leads and consults remained strong, but consumers stayed hesitant to convert from interest and quotes to purchase. Q4 same-store sales trends are better than year-to-date, and management sees a bigger-than-expected GLP-1 opportunity, with GLP-1 users already converting better than non-GLP-1 users.
How does the surge in skin-excision interest play out within your centers and surgeon base, and can AirSculpt capture the economics of these procedures?
Both surgeon interest and expertise are strong positives; management even slowed the pilot to fewer locations than surgeon demand supported. The network of over 80 plastic and cosmetic surgeons is capable, and many have already performed these procedures in private practice or prior roles, so there are no concerns on delivering them within AirSculpt centers.
Does your marketing or brand awareness need to change to go after this new subsegment of GLP-1 patients?
Yes - marketing and sales will change to get the messaging and targeting right for GLP-1 users and loose-skin patients at the right point in the GLP-1 journey. Fat removal is also a large opportunity, since GLP-1 use causes uneven weight and volume loss and patients keep coming in to remove stubborn fat deposits the medication could not address.
More on Airsculpt Technologies, Inc.
Reported 2025-11-07 · figures from the Airsculpt Technologies, Inc. Q3 2025 earnings call.
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.